Sanofi (NASDAQ:SNY) is a global biopharmaceutical company headquartered in Paris, France, with a comprehensive portfolio spanning pharmaceuticals, vaccines and consumer healthcare products. Established in its current form in 2004 through the merger of Sanofi-Synthélabo and Aventis, the company has built a strong research-and-development platform focused on delivering innovative treatments for a range of therapeutic areas. Sanofi’s pharmaceutical business includes specialty care drugs for diabetes, cardiovascular disease, oncology and immunology, while its vaccines division, Sanofi Pasteur, ranks among the world’s largest vaccine producers, supplying immunizations against influenza, polio, meningitis and dengue. The consumer healthcare arm offers a variety of over-the-counter products in wellness, allergy and pain relief.
Research and development sit at the core of Sanofi’s operations, driving investments in biologics, monoclonal antibodies and gene therapies. The company collaborates with academic institutions, biotech firms and public-private partnerships to advance new modalities in areas such as rare diseases, multiple sclerosis and central nervous system disorders. Sanofi also deploys advanced manufacturing capabilities, leveraging continuous processing and single-use technologies to scale biologics production efficiently.
With a presence in more than 100 countries, Sanofi serves diverse markets across Europe, North America, Latin America, Asia-Pacific and the Middle East. Regional research hubs and manufacturing sites are strategically located to support both global clinical trials and local public health initiatives. Sanofi’s vaccine business regularly partners with governments and health organizations to address emerging infectious diseases and improve immunization coverage in underserved regions.
Under the leadership of Chief Executive Officer Paul Hudson, appointed in 2019, Sanofi has sharpened its strategic focus on specialty care and vaccines, streamlining its portfolio to advance high-impact medicines for patients. The executive team emphasizes sustainable growth through disciplined capital allocation, new-launch execution and digital transformation across R&D, manufacturing and commercial operations. As Sanofi continues to evolve, it remains committed to leveraging science and innovation to meet global healthcare challenges.
